March 30, 2010; 74 (13) Articles
Ibudilast in relapsing-remitting multiple sclerosis
A neuroprotectant?
F. Barkhof, H.E. Hulst, J. Drulović, B.M.J. Uitdehaag, K. Matsuda, R. Landin
First published March 3, 2010, DOI: https://doi.org/10.1212/WNL.0b013e3181d7d651
F. Barkhof
H.E. Hulst
J. Drulović
B.M.J. Uitdehaag
K. Matsuda
Ibudilast in relapsing-remitting multiple sclerosis
A neuroprotectant?
F. Barkhof, H.E. Hulst, J. Drulović, B.M.J. Uitdehaag, K. Matsuda, R. Landin
Neurology Mar 2010, 74 (13) 1033-1040; DOI: 10.1212/WNL.0b013e3181d7d651
Citation Manager Formats
Make Comment
See Comments

Article Information
vol. 74 no. 13 1033-1040
PubMed:
Print ISSN:
Online ISSN:
History:
- First Published March 3, 2010.
Article Versions
- Previous version (March 3, 2010 - 12:31).
- You are viewing the most recent version of this article.
Copyright & Usage:
© 2010
Author Disclosures
- F. Barkhof, MD, PhD,
- H.E. Hulst, MSc,
- J. Drulović, MD,
- B.M.J. Uitdehaag, MD, PhD,
- K. Matsuda, MD,
- R. Landin, PhD and
- For the MN166-001 Investigators
- F. Barkhof, MD, PhD,
- H.E. Hulst, MSc,
- J. Drulović, MD,
- B.M.J. Uitdehaag, MD, PhD,
- K. Matsuda, MD,
- R. Landin, PhD and
- For the MN166-001 Investigators
- From the Image Analysis Center (F.B., H.E.H.) and MS Centre (B.M.J.U.), VU University Medical Center, Amsterdam, The Netherlands; Klinički Centar Srbije (J.D.), Institut za Neurologiju Beograd, Serbia; and Medicinova Inc. (K.M., R.L.), San Diego, CA.
- Address correspondence and reprint requests to Dr. F. Barkhof, Department of Radiology, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands f.barkhof{at}vumc.nl.
Article usage
Letters: Rapid online correspondence
No comments have been published for this article.
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Null Hypothesis
Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1aRaymond Hupperts, Joost Smolders, Reinhold Vieth et al.Neurology, October 08, 2019 -
Article
Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS StudyRobert T. Naismith, Robert A. Bermel, Christopher S. Coffey et al.Neurology, December 02, 2020 -
Articles
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapsesP. W. O’Connor, D. Li, M. S. Freedman et al.Neurology, March 27, 2006 -
Article
Epigallocatechin Gallate in Progressive MSA Randomized, Placebo-Controlled TrialRebekka Rust, Claudia Chien, Michael Scheel et al.Neurology: Neuroimmunology & Neuroinflammation, February 23, 2021